Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Rhein

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7380   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    359 result(s) found for: Rhein. Displaying page 1 of 18.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2018-000439-29 Sponsor Protocol Number: CCP-020-101 Start Date*: 2018-06-04
    Sponsor Name:Castle Creek Pharmaceuticals, LLC
    Full Title: A Multi-center Study to Evaluate the Pharmacokinetics of Diacerein and Rhein and the Safety of Diacerein after Maximum Use, Topical Administration of CCP-020 (Diacerein 1% ointment) to Patients wit...
    Medical condition: Epidermolysis Bullosa (EB)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10014989 Epidermolysis bullosa PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed) NL (Ongoing)
    Trial results: View results
    EudraCT Number: 2011-004148-23 Sponsor Protocol Number: 1218.22 Start Date*: 2013-10-04
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: A multicenter, international, randomized, parallel group, double-blind, placebo-controlled, cardiovascular safety and renal microvascular outcome study with linagliptin, 5 mg once daily in patients...
    Medical condition: Diabetes Mellitus type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) GB (Completed) CZ (Completed) NL (Completed) HU (Completed) ES (Completed) PL (Completed) BG (Completed) HR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002254-20 Sponsor Protocol Number: 1297.9 Start Date*: 2017-08-04
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: VOLTAIRE-X: Pharmacokinetics, safety, immunogenicity and efficacy of BI 695501 versus Humira® in patients with moderate to severe chronic plaque psoriasis: a randomized, double-blind, parallel-arm,...
    Medical condition: moderate to severe chronic plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Completed) HU (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-000613-79 Sponsor Protocol Number: 1297.12 Start Date*: 2016-10-25
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: Efficacy, Safety, and Immunogenicity of BI 695501 versus Humira® in Patients with Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Compar...
    Medical condition: Moderate to Severe Chronic Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) SK (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2010-024534-38 Sponsor Protocol Number: Version 1.1 Start Date*: 2011-07-19
    Sponsor Name:Medizinische Universität Wien, Abteilung für Herzchirurgie
    Full Title: Pilot-Trial: Dabigatran as an alternative anticoagulant in patients with left ventricular assist device
    Medical condition: patients with implanted left ventricular assist device
    Disease: Version SOC Term Classification Code Term Level
    13.1 10042613 - Surgical and medical procedures 10052374 Left ventricular assist device insertion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003890-27 Sponsor Protocol Number: 69.52 Start Date*: 2012-09-26
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A multi-centre, double-blind, randomised, parallel group study to assess the efficacy and safety of multiple doses of topically applied hyperemisation-inducing ointment (2 cm ointment line per appl...
    Medical condition: Acute low back pain
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-002579-17 Sponsor Protocol Number: WR 01102004 Start Date*: 2006-11-08
    Sponsor Name:Medizinische Klinik B, Herzzentrum Ludwigshafen
    Full Title: A double-blind, randomised placebo controlled study of the effects of Acarbose on endothelial function, hemostatic and fibrinolytic plasmatic factors in patients with stable coronary artery disease...
    Medical condition: 1. To study the effect of Acarbose treatment on endothelial function as a potential mechanism for the beneficial effects of better postprandial glycemic control in patients with impaired glucose to...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000490-29 Sponsor Protocol Number: No.1, 1.1.2006 Start Date*: 2006-03-27
    Sponsor Name:Insitute for Clinical and Experimental Medicine
    Full Title: Effect of 3-week AT-1 receptor blockade on insulin resistance in relation to endocrine activity of adipose tissue in patients with insulin resistance
    Medical condition: Metabolic syndrome with impaired glucose homeostasis nad prehypertension
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002278-11 Sponsor Protocol Number: 1245.110 Start Date*: 2017-06-19
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Frac...
    Medical condition: Heart failure (HF) with preserved ejection fraction (EF).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) CZ (Completed) NL (Completed) ES (Completed) BE (Completed) GB (GB - no longer in EU/EEA) LT (Prematurely Ended) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-002280-34 Sponsor Protocol Number: 1245.121 Start Date*: 2017-06-19
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fracti...
    Medical condition: Heart failure (HF) with reduced ejection fraction (EF).
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) FR (Completed) ES (Completed) HU (Completed) CZ (Completed) BE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-002275-28 Sponsor Protocol Number: 1237.19 Start Date*: 2014-11-18
    Sponsor Name:Boehringer Ingelheim Finland Ky
    Full Title: A randomised, double-blind, active-controlled parallel group study to evaluate the effect of 52 weeks of once daily treatment of orally inhaled tiotropium + olodaterol fixed dose combination compar...
    Medical condition: chronic obstructive pulmonary disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004855 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) IT (Completed) SE (Completed) PT (Completed) DK (Completed) BE (Completed) NL (Completed) HU (Completed) GB (Completed) ES (Completed) AT (Completed) IE (Completed) LT (Completed) CZ (Completed) LV (Completed) SK (Completed) DE (Completed) SI (Completed) GR (Completed) BG (Completed) HR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-005117-23 Sponsor Protocol Number: 1311.3 Start Date*: 2016-04-14
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: BI 655066/ABBV-066 (risankizumab) versus Ustekinumab and placebo comparators in a randomized double blind trIal for Maintenance use in Moderate to severe plaque type psoriasis (UltIMMa-1)
    Medical condition: Psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2019-004756-11 Sponsor Protocol Number: EP0009 Start Date*: 2020-01-08
    Sponsor Name:UCB Pharma SA
    Full Title: A multi-center, open-label, uncontrolled, long-term, extension study to evaluate the safety and efficacy of Lacosamide as adjunctive therapy in Japanese and Chinese adults with partial-onset seizur...
    Medical condition: Partial Onset Seizures
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-005025-20 Sponsor Protocol Number: CR0012 Start Date*: 2018-03-21
    Sponsor Name:UCB Biosciences, Inc.
    Full Title: An open-label, multicenter study to assess the safety of certolizumab pegol in children and adolescents with active Crohn's Disease who completed C87035 or who were terminated from C87035 when the ...
    Medical condition: Crohn´s Disease
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-000095-42 Sponsor Protocol Number: 1199.52 Start Date*: 2014-10-08
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therap...
    Medical condition: Patients with metastatic colorectal cancer refractory to standards therapies
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LU (Completed) IT (Completed) SE (Completed) AT (Completed) DK (Completed) BE (Completed) DE (Completed) PT (Completed) NL (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-002894-48 Sponsor Protocol Number: 1301.1 Start Date*: 2012-09-14
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: Efficacy, pharmacokinetics, and safety of BI 695500 versus rituximab in patients with moderately to severely active rheumatoid arthritis: a randomized, double-blind, parallel arm, multiple dose, ac...
    Medical condition: Moderately to severely active Rheumatoid Arthritis that has had an inadequate response or intolerance to conventional DMARD therapy including at least one TNF inhibitor
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004870 10039075 Rheumatoid arthritis and associated conditions HLT
    17.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) EE (Completed) PT (Prematurely Ended) NL (Prematurely Ended) BE (Completed) DE (Prematurely Ended) HU (Prematurely Ended) NO (Prematurely Ended) GR (Completed) ES (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002902-29 Sponsor Protocol Number: 1311.6 Start Date*: 2014-01-09
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: A phase II, multicenter, randomized, double-blind, multiple dose, placebo-controlled, parallel-group study to evaluate the efficacy, pharmacokinetics, and safety of BI 655066, an IL-23 p19 antagoni...
    Medical condition: Crohn's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) IE (Completed) ES (Completed) NL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000935-98 Sponsor Protocol Number: 1249.7 Start Date*: 2011-10-19
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A single dose, placebo-controlled, randomised, double-blind double dummy, 5-way crossover (7 treatments, 5 periods incomplete block), including 24-h pulmonary function tests, pharmacodynamic compar...
    Medical condition: Asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-004932-20 Sponsor Protocol Number: 1311.14 Start Date*: 2015-06-05
    Sponsor Name:SCS Boehringer Ingelheim Comm.V
    Full Title: A phase IIa, randomized, double-blind, placebo controlled, parallel group study to assess the safety and efficacy of subcutaneously administered BI 655066 (risankizumab) as add-on therapy over 24 w...
    Medical condition: Severe Asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) HU (Completed) NL (Completed) DE (Completed) PL (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-002634-41 Sponsor Protocol Number: 1297.3 Start Date*: 2016-01-07
    Sponsor Name:Boehringer Ingelheim International GmbH
    Full Title: Long-term assessment of safety, efficacy, pharmacokinetics and immunogenicity of BI 695501 in patients with rheumatoid arthritis (RA): an open-label extension trial for patients who have completed ...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) DE (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Aug 13 11:31:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA